Skip to main content
main-content

08.01.2019 | Review | Ausgabe 6/2018

Immunologic Research 6/2018

The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results

Zeitschrift:
Immunologic Research > Ausgabe 6/2018
Autoren:
Poupak Fallahi, Silvia Martina Ferrari, Simona Piaggi, Michaela Luconi, Giulia Cantini, Stefania Gelmini, Giusy Elia, Ilaria Ruffilli, Alessandro Antonelli
Wichtige Hinweise
Take-home messages:
• The treatment with IFNγ+TNFα induces a marked release of CXCL9, and to a lesser extent of CXCL11, by primary thyrocytes from PTC. A discrepancy is present between the stimulatory role of PPARγ agonists on CXCL9 and CXCL11 release and the inhibitory effect on PTC proliferation. Furthermore, CXCL9 and CXCL11 are able to inhibit the proliferation and migration of primary PTC cells.
• The use of CXCL9 or CXCL11 as antineoplastic agents in PTC remains to be explored.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Our study demonstrates that (C-X-C motif) ligand 9 and 11 (CXCL9, CXCL11) chemokines were absent basally in non-neoplastic thyroid (TFC) and papillary thyroid carcinoma (PTC) cells. Interferon (IFN)γ induced the chemokine secretion in TFC and PTC, while tumor necrosis factor (TNF)α induced it only in PTC. IFNγ+TNFα induced a synergistic chemokines release in PTC, and at a lower level in TFC. Peroxisome proliferator-activated receptor (PPAR)γ agonists suppressed dose-dependently IFNγ+TNFα-induced chemokine release in TFC, while stimulated it in PTC. PPARγ knocking down, by RNA interference technique in PTC cells, abolished the effect of PPARγ agonists on chemokines release. In PTC cells, PPARγ agonists reduced proliferation, and CXCL9 or CXCL11 (100 and 500 pg/mL) reduced proliferation and migration (P < 0.01, for all). In conclusion, in PTC cells: (a) IFNγ+TNFα induced a marked release of CXCL9 and CXCL11; (b) PPARγ agonists stimulated CXCL9 and CXCL11 secretion, while inhibited proliferation; (c) CXCL9 and CXCL11 inhibited proliferation and migration. The use of CXCL9 or CXCL11 as antineoplastic agents in PTC remains to be explored.

Highlights

• IFNγ and IFNγ+TNFα induce dose-dependently CXCL9 (and less CXCL11) in PTC cells.
• Rosi and Pio dose-dependently inhibit the PTC cells proliferation.
• Rosi and Pio (at variance of normal TFC) stimulate CXCL9 or CXCL11 secretion.
• CXCL9 or CXCL11 induce a significant antiproliferative effect in PTC cells.
• Chemokines induced by IFNγ (CXCL9 or CXCL11) inhibit migration in PTC cells.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Jetzt e.Med zum Sonderpreis bestellen!

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 6/2018

Immunologic Research 6/2018 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.


 

Neu im Fachgebiet HNO

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise